New Consumer Cannabidiol (CBD) Products Report Released
The recent report by the Advisory Council on the Misuse of Drugs (ACMD) considers: the dose at which cannabinoids have no detectable psychoactive effect on humans; the analytical capabilities to test for these cannabinoids; and the feasibility of production of consumer CBD products with low levels of controlled cannabinoids.
The report is now under review by the Home Office. The APPG meanwhile has asked the Home Office to delay any decision in regard to dosage until the APPG has produced its own report on dosage from geographies from around the world with sustainable CBD industries.